CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 83 enrolled
Drug / intervention
sunitinibdrug
Likely dose
sunitinib 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00471276
NCT00471276Phase 2Completed
CompareCT.gov

A Phase II Study Of Sunitinib Malate Single Agent For The Treatment Of Women With Advanced Breast Cancer

Pfizer·interventional·Posted May 9, 2007·Updated Jul 25, 2011

In Brief

A Phase 2 clinical trial evaluating sunitinib for Breast Neoplasms. Completed, enrolled 83 participants across 31 sites.

Detailed Summary

Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 9, 2007
Enrollment StartAug 1, 2007
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.1 years ago

Interventions

sunitinibdrug

sunitinib (Sutent), 37.5 mg, daily dosing